middle.news
How Will Anteris’ ASX Waiver and Trial Delay Shape Its Future?
8:36am on Tuesday 30th of September, 2025 AEST
•
Healthcare
Read Story
How Will Anteris’ ASX Waiver and Trial Delay Shape Its Future?
8:36am on Tuesday 30th of September, 2025 AEST
Key Points
Shareholders approve ASX waiver for new securities issuance
PARADIGM pivotal trial patient enrolment delayed to Q4 2025
FDA requested additional bench testing data, now addressed
Regulatory submissions progressing in Europe
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Anteris Technologies Global (ASX:AVR)
OPEN ARTICLE